Evidence map›Paper›PMID 38667158›Full record

ArticleBiosensors2024

Wearable Movement Exploration Device with Machine Learning Algorithm for Screening and Tracking Diabetic Neuropathy-A Cross-Sectional, Diagnostic, Comparative Study.

Goran Radunovic, Zoran Velickovic, Slavica Pavlov-Dolijanovic, Sasa Janjic, Biljana Stojic, Irena Jeftovic Velkova, Nikola Suljagic, Ivan Soldatovic

Abstract readComparative Study
In one paragraph

Article in Biosensors, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Goran RadunovicInstitute of Rheumatology, 11000 Belgrade, Serbia.
Zoran VelickovicInstitute of Rheumatology, 11000 Belgrade, Serbia.ORCID 0000-0002-0590-8590
Slavica Pavlov-DolijanovicInstitute of Rheumatology, 11000 Belgrade, Serbia.
Sasa JanjicInstitute of Rheumatology, 11000 Belgrade, Serbia.
Biljana StojicInstitute of Rheumatology, 11000 Belgrade, Serbia.
Irena Jeftovic VelkovaDIVS Neuroinformatics DOO, 11000 Belgrade, Serbia.
Nikola SuljagicDIVS Neuroinformatics DOO, 11000 Belgrade, Serbia.
Ivan SoldatovicFaculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0003-4893-1683

Funding

Innovation Found of Serbia
6 · The paper itself

Abstract

backgroundDiabetic neuropathy is one of the most common complications of diabetes mellitus. The aim of this study is to evaluate the Moveo device, a novel device that uses a machine learning (ML) algorithm to detect and track diabetic neuropathy. The Moveo device comprises 4 sensors positioned on the back of the hands and feet accompanied by a mobile application that gathers data and ML algorithms that are hosted on a cloud platform. The sensors measure movement signals, which are then transferred to the cloud through the mobile application. The cloud triggers a pipeline for feature extraction and subsequently feeds the ML model with these extracted features.

methodsThe pilot study included 23 participants. Eleven patients with diabetes and suspected diabetic neuropathy were included in the experimental group. In the control group, 8 patients had suspected radiculopathy, and 4 participants were healthy. All participants underwent an electrodiagnostic examination (EDx) and a Moveo examination, which consists of sensors placed on the feet and back of the participant's hands and use of the mobile application. The participant performs six tests that are part of a standard neurological examination, and a ML algorithm calculates the probability of diabetic neuropathy. A user experience questionnaire was used to compare participant experiences with regard to both methods.

resultsThe total accuracy of the algorithm is 82.1%, with 78% sensitivity and 87% specificity. A high linear correlation up to 0.722 was observed between Moveo and EDx features, which underpins the model's adequacy. The user experience questionnaire revealed that the majority of patients preferred the less painful method.

conclusionsMoveo represents an accurate, easy-to-use device suitable for home environments, showing promising results and potential for future usage.

Indexed as

AlgorithmsDiabetic NeuropathiesMachine LearningWearable Electronic DevicesAdultAgedCross-Sectional StudiesFemaleHumansMaleMiddle AgedMovementPilot Projectsdiabetic neuropathyscreeningtrackingwearable device

Identifiers

PMID38667158
PMCPMC11047826

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.